HUP0301693A2 - Antitest citokin-citokin inhibitorból (szelektokin) álló fúziós protein célspecifikus prodrugként történő alkalmazásra - Google Patents

Antitest citokin-citokin inhibitorból (szelektokin) álló fúziós protein célspecifikus prodrugként történő alkalmazásra

Info

Publication number
HUP0301693A2
HUP0301693A2 HU0301693A HUP0301693A HUP0301693A2 HU P0301693 A2 HUP0301693 A2 HU P0301693A2 HU 0301693 A HU0301693 A HU 0301693A HU P0301693 A HUP0301693 A HU P0301693A HU P0301693 A2 HUP0301693 A2 HU P0301693A2
Authority
HU
Hungary
Prior art keywords
cytokine
selectokine
target
fusion protein
antibody
Prior art date
Application number
HU0301693A
Other languages
English (en)
Inventor
Matthias Grell
Dieter Moosmayer
Peter Scheurich
Thomas Wüst
Original Assignee
Pfizenmaier, Klaus
Universität Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizenmaier, Klaus, Universität Stuttgart filed Critical Pfizenmaier, Klaus
Publication of HUP0301693A2 publication Critical patent/HUP0301693A2/hu
Publication of HUP0301693A3 publication Critical patent/HUP0301693A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tumorellenes és/vagy immunmoduláló citokintulajdonságokkal rendelkező olyan polipeptidre vonatkozik, amely invivo feldolgozás által aktiválható. Az említett polipeptid specifikusbiológiai aktivitású központi régiót tartalmaz, amelynek C-terminálisvégén egy feldolgozásra szolgáló egység és egy inhibitor doménhelyezkedik el, N-terminális végén pedig egy olyan régiót tartalmaz,amely egy sejtfelületen lévő makromolekulát vagy egy extracellulárismátrix-alkotórészt szelektíven felismer. Ó
HU0301693A 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug HUP0301693A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (2)

Publication Number Publication Date
HUP0301693A2 true HUP0301693A2 (hu) 2003-08-28
HUP0301693A3 HUP0301693A3 (en) 2005-11-28

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301693A HUP0301693A3 (en) 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Country Status (22)

Country Link
US (1) US20040053829A1 (hu)
EP (1) EP1317556A1 (hu)
JP (1) JP2004508828A (hu)
KR (1) KR20030048041A (hu)
CN (1) CN1214115C (hu)
AU (1) AU2001293819A1 (hu)
BG (1) BG107613A (hu)
BR (1) BR0113928A (hu)
CA (1) CA2422759A1 (hu)
DE (1) DE10045592A1 (hu)
EE (1) EE200300100A (hu)
HR (1) HRP20030192A2 (hu)
HU (1) HUP0301693A3 (hu)
IL (1) IL154185A0 (hu)
MX (1) MXPA03002229A (hu)
NO (1) NO20031185L (hu)
PL (1) PL360540A1 (hu)
RU (1) RU2003106429A (hu)
SK (1) SK2812003A3 (hu)
WO (1) WO2002022833A1 (hu)
YU (1) YU18903A (hu)
ZA (1) ZA200302008B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
KR20050108349A (ko) * 2003-02-06 2005-11-16 마이크로메트 에이지 영속적인 티 세포 반응을 유도하는 삼량체 폴리펩티드 구조물
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
WO2010096838A2 (en) * 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proproteins and methods of use thereof
JP2021515599A (ja) * 2018-03-09 2021-06-24 アスクジーン・ファーマ・インコーポレイテッドＡｓｋＧｅｎｅ Ｐｈａｒｍａ， Ｉｎｃ． 新規のサイトカインプロドラッグ
CA3100018A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
JP2021530243A (ja) * 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
JP2022532217A (ja) 2019-05-14 2022-07-13 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
KR20220020879A (ko) * 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
BR0113928A (pt) 2003-07-22
MXPA03002229A (es) 2005-06-20
WO2002022833A1 (de) 2002-03-21
EP1317556A1 (de) 2003-06-11
KR20030048041A (ko) 2003-06-18
PL360540A1 (en) 2004-09-06
RU2003106429A (ru) 2004-08-27
HRP20030192A2 (en) 2005-10-31
CA2422759A1 (en) 2003-03-17
DE10045592A1 (de) 2002-03-28
IL154185A0 (en) 2003-07-31
CN1458977A (zh) 2003-11-26
US20040053829A1 (en) 2004-03-18
HUP0301693A3 (en) 2005-11-28
CN1214115C (zh) 2005-08-10
EE200300100A (et) 2005-02-15
ZA200302008B (en) 2004-06-25
NO20031185L (no) 2003-05-05
YU18903A (sh) 2006-05-25
AU2001293819A1 (en) 2002-03-26
BG107613A (bg) 2003-12-31
NO20031185D0 (no) 2003-03-14
SK2812003A3 (en) 2003-11-04
JP2004508828A (ja) 2004-03-25

Similar Documents

Publication Publication Date Title
HUP0301693A2 (hu) Antitest citokin-citokin inhibitorból (szelektokin) álló fúziós protein célspecifikus prodrugként történő alkalmazásra
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CY1115142T1 (el) Χρηση πεπτιδιων παραγωγων της καθελισιδινης ll-37 για τη θεραπεια χρονιων πληγων
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
JP2005516072A5 (hu)
DE60323210D1 (en) Eukaryontische signalsequenzen für polypeptid-expr
EP2360180A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
MXPA06003474A (es) Agonistas de receptores de melanocortina.
WO2002101045A3 (en) Vanilloid receptor-related nucleic acids and polypeptides
DK1210430T3 (da) MUC-1-afledte peptider
NO20060093L (no) Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
WO2007014744A3 (en) C-terminal tnf-family ligand (ctl) -prodrug
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
ATE495247T1 (de) Chromoprotein und fluoroproteine
EA200600561A1 (ru) Фармацевтический препарат для лечения шока
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
WO2005017188A3 (en) Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
HUP0400262A2 (hu) Glikopeptidek, előállításuk és alkalmazásuk szklerózis multiplex kezelésében

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees